Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis

Table 3 Dysplasia or colorectal cancer in primary sclerosing cholangitis - inflammatory bowel disease n (%)

Ref.	IBD (n)	PSC-IBD (n)	Country	Dysplasia		Risk/incidence		Proximal colon1		Age dysplasia diagnosis (yr)		IBD duration (yr)		Diagnosis IBD
				IBD	PSC-IBD	IBD	PSC-IBD	IBD	PSC-IBD	IBD	PSC-IBD	IBD	PSC-IBD
Broomé et al[45], 1995	80	40	Sweden	7 (8.8)	11 (27.5)	CR = 10 yr: 2%	CR = 10 yr: 9%	NA	NA	NA	NA	26.02	18.02	IBD34
Gurbuz et al[49], 1995	0	35	United States	NA	13 (37.1)	NA	CR = 10 yr: 0%	NA	NA	NA	51.42	NA	12.22	IBD34
Brentnall et al[56], 1996	25	20	United States	4 (16)	9 (45)	NA	OR = 4.9	NA	NA	NA	NA	NA	20.02	IBD34
Loftus et al[29], 1996	0	143	United States	NA	27 (18.9)	NA	CR = 20 yr: 17%	NA	42.9%5	NA	41.06	NA	NA	IBD34
Kornfeld et al[48], 1997	0	58	Sweden	NA	5 (8.6)	NA	NA	NA	NA	NA	NA	NA	NA	IBD7
Leidenius et al[50], 1997	45	45	Finland	4 (8.9)	13 (28.9)	CR = 10 yr: 3%	CR = 10 yr: 11%	NA	NA	NA	NA	17.52	11.06	IBD34
Marchesa et al[54], 19978	1185	27	United States	145 (12.2)	18 (66.7)	NA	RR = 10.4	40.8%5	100.0%5	NA	NA	NA	NA	IBD4
Shetty et al[84], 1999	196	132	United States	11 (5.6)	33 (25)	RR = 1	RR = 3.15	20.0%5	76.5%5	NA	NA	NA	NA	IBD34
Lindberg et al[46], 2001	103	19	Sweden	31 (30.1)	12 (63.2)	CR = 20 yr: 16%	CR = 20 yr: 32%	32.3%	69.2%	NA	NA	NA	NA	IBD34
Bergquist et al[108], 2002	0	477	Sweden	NA	35 (7.3)	NA	SIR = 10.3	NA	NA	NA	NA	NA	NA	IBD34
Loftus et al[11], 2005	142	71	United States	15 (10.6)	18 (25.4)	CP = 10 yr: 20%	CP = 10 yr: 53%	50%5	28.6%5	NA	NA	12.16	12.76	IBD34
Kaplan et al[109], 2007	0	45	Canada	NA	5 (11.1)	NA	IR = 3.1	NA	NA	NA	NA	NA	NA	IBD34
Lepistö et al[16], 2008	389	52	Finland	63 (16.2)	17 (32.7)	CR = 20 yr: 0.39	CR = 20 yr: 0.43	NA	NA	NA	NA	NA	NA	IBD4
Sokol et al[15], 2008	150	75	France	2 (1.3)	10 (13.3)	CR = 25 yr: 1.5%	CR = 25 yr: 25.6%	0.0%5	100.0%5	NA	NA	44.42	17.42	IBD34
Terg et al[51], 2008	64	39	Argentina	2 (3.1)	7 (17.9)	CR = 10 yr: 2.0%	CR = 10 yr: 11%	NA	NA	NA	NA	NA	NA	IBD34
Claessen et al[52], 2009	0	126	The Netherlands	NA	35 (27.8)	NA	CR = 10 yr: 9%	NA	63.0%5	NA	NA	NA	12.66	IBD34
Lindström et al[38], 2011	46	28	Sweden	3 (6.5)	9 (32.1)	NA	OR = 6.78	0.0%	66.0%	NA	NA	10.06	12.06	IBD34
Braden et al[58], 2012	216	166	United Kingdom	14 (6.5)	14 (8.4)	CIR = 2.9%	CIR = 7.5%	30.0%	35.7%	NA	NA	NA	NA	IBD34
Imam et al[53], 2012	0	784	United States	NA	10 (1.3)	NA	I = 0.4/yr	NA	60.0%	NA	37.42	NA	NA	IBD34
Jess et al[55], 2012	47374	NA	Denmark	329 (0.7)	9 (?)9	RR = 1.07 (UC)	RR = 9.13	38.0%	100.0%	71.66	64.06	NA	13.76	IBD7
de Valle et al[79], 2012	0	152	Sweden	NA	3 (2.0)	NA	SIR = 4.31	NA	NA	NA	NA	NA	NA	IBD34
Boonstra et al[22], 2013	722	402	The Netherlands	7 (1)	19 (4.7)	SIR = 1.2	SIR = 8.6	NA	NA	596	39.06	4.06	15.06	IBD34

¹From cecum to splenic flexura;

²Mean;

³Endoscopic findings;

⁴Histological findings (biopsies);

⁵For CRC only;

⁶Median;

⁷Unknown or not reviewed;

⁸Abstract;

⁹Population based study, amount of PSC-IBD patients not specified. RR: Relative risk; CR: Cumulative risk; CP: Cumulative probability; CIR: Cumulative incidence rate; SIR: Standard incidence ratio; OR: Odds ratio; IR: Incidence rate; I: Incidence; NA: Not available; PSC: Primary sclerosing cholangitis; IBD: Inflammatory bowel disease.